RxDoctor Payments Data

Mary Ngugi

Psychiatric/Mental Health · South Bend, INNPI 1972106615

Payments from drug & device makers

$1,957in general payments, 2019–2025

Across 92 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$432
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$224
  • Lundbeck LLC$221
  • Otsuka America Pharmaceutical, Inc.$177
  • Vanda Pharmaceuticals Inc.$163
  • Johnson & Johnson$136
  • plus $605 from 12 others

What the payments were for

  • Food & beverage$1,84594%
  • Education$1126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,957 in reported general payments places this provider in the 70th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$19,613
Medicare patients
68
Services billed
254

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate130$429,296
Abilify MaintenaAripiprazole107$311,395
PerserisRisperidone17$51,142
VraylarCariprazine Hcl35$50,583
VivitrolNaltrexone Microspheres23$38,445
Aripiprazole250$25,657
RexultiBrexpiprazole18$24,326
LybalviOlanzapine/Samidorphan Malate12$20,537
Divalproex Sodium ErDivalproex Sodium215$9,504
VyvanseLisdexamfetamine Dimesylate22$8,456
Olanzapine84$8,374
Clozapine124$5,801
Quetiapine Fumarate321$5,063
Paliperidone ErPaliperidone32$4,995
Haloperidol Decanoate61$4,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$136$429,296130 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$177$335,721125 claims
Alkermes, Inc.Vivitrol, Lybalvi$118$58,98235 claims
Indivior Inc.Perseris$17$51,14217 claims
AbbVieVraylar$432$50,58335 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$45$8,45622 claims
Almatica Pharma LLCSertraline Hcl$26$1,669178 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →